Status:
UNKNOWN
Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients
Lead Sponsor:
Medical University of Gdansk
Conditions:
Critical Illness
Thrombosis
Eligibility:
All Genders
18-85 years
Brief Summary
Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in ...
Eligibility Criteria
Inclusion
- Circulatory failure
- Supported by continuous infusion of noradrenaline or noradrenaline and argipressin
- Receiving subcutaneous dalteparin for the prevention of venous thromboembolism.
Exclusion
- Contraindications for dalteparin
- Severe coagulopathy
- Acute or subacute bacterial endocarditis
- Pregnant women
- BMI (body mass index) \> 30kg/m2
- Chronic kidney disease with eGFR (estimated glomerular filtration rate) \< 30 ml/min/1.73 m2
- Renal replacement therapy
- The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin
Key Trial Info
Start Date :
May 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06055907
Start Date
May 15 2023
End Date
September 1 2024
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care
Gdansk, Poland, 80-214